This resource has been initiated and supported by Alturix Ltd, who have had the opportunity to review it for factual accuracy but have had no input into its content.

 

INTRODUCTION

Sputum production is a common feature of chronic obstructive pulmonary disease (COPD), but for some patients, it is difficult to clear, leaving them potentially vulnerable to respiratory infections.

This resource will examine the rationale for mucolytic therapy in the management of patients with COPD. It will discuss the use of mucolytic therapies based on current evidence, and where the use of mucolytics is recommended in international and UK COPD guidelines.

LEARNING OBJECTIVES

After working through this resource, you will be more familiar with:

• Sputum production and clearance in patients with chronic obstructive pulmonary disease (COPD)
• The physiological process of mucus secretion
• Evidence for the use of mucolytics in patients with COPD
• Guideline recommendations
• Non-pharmacological interventions to improve symptoms of COPD

This resource is provided at an intermediate level. Read the article and answer the self-assessment questions, and reflect on what you have learned.

Complete the resource to obtain a certificate to include in your revalidation portfolio. You should record the time spent on this resource in your CPD log.

Job code: AL0313 Date of preparation: September 2023

This promotional module has been initiated, funded and reviewed solely by Alturix

https://alturix.com/contact-us/

Prescribing information for NACSYS® is available here

Reporting adverse effects: Adverse events should be reported. Reporting forms and information can be founds at https://yellowcard.mhra.gov.uk or seatch for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Alturix Limited at [email protected] and +44 (0)1903 038 083